Tag Archives: Mayo

BIO IPCC Spring Conference Program Announced

IPCC Logo

BIO’s 2015 IP Counsels Committee Spring Conference & Meeting will be held April 15-17 in St. Louis, Missouri, at the Four Seasons St. Louis Hotel. The biannual conference offers timely, relevant educational sessions on the latest issues in the biotech IP sector, informal networking events designed to promote discussion and foster relationships among industry colleagues, and practical tips for attendees to use the next day. Attendees will hear from the foremost experts in biotech IP Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

BIO Deputy General Counsel Remarks on Revised Eligibility Guidance

Supreme Court

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property recently spoke at the U.S. Patent and Trademark Office’s public forum on patent-eligible subject matter. The forum was a chance for the Office to receive public feedback regarding the most recently revised Eligibility Guidance for determining subject matter under 35 U.S.C. 1010. Biotechnology advocates are concerned that PTO examiners have interpreted recent decisions by the U.S. Supreme Court, including those in Alice Corp, Myriad, and Mayo Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

USPTO Issues New Myriad Guidance

Kaylee_dna_115x76

On Tuesday, December 16 the United States Patent and Trademark Office issued a revised guidance on subject matter eligibility under § 101 in light of recent Supreme Court Decisions in Alice v. CLS Bank, Mayo, and Myriad. These new guidelines are a response to extensive feedback provided from industry leaders and inventors over the last several months. (BIO provided both initial and supplemental comments on the Office’s March Subject Matter Eligibility Guidance). Public comments on the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

Patently Biotech’s Top Articles of 2014

shutterstock_26191726

It’s been a whirlwind year for IP. From international trade negotiations, to revised PTO guidelines and dropping patent case stats, intellectual property is on the brain and in the news. Here are Patently Biotech’s top blog posts of 2014: TPP and IP: The Economic Benefits of a Pacific Trade Agreement Should the USPTO allow the patenting of living organisms? Gene Patent Questions Remain: USPTO Issues Examiner Guidelines Stopped at the Threshold: A New Study Reports Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

PTO Patent Examinations in the wake of Mayo and Myriad

stopped-media-115x76

Biotech patent applicants are finding themselves in uncharted waters.   After the Supreme Court’s decisions in Mayo Collaborative Svs. v. Prometheus Labs and Ass’n for Molecular Pathology v. Myriad Genetics, companies have been trying to understand how these decisions will impact the industry. A recent study supported by BIO, in collaboration with Bloomberg BNA and the law firm of Robins, Kaplan, Miller & Ciresi analyzed how Mayo and Myriad have changed patent eligibility for biotechnology. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,